Skip to main content
Erschienen in: BMC Women's Health 1/2023

Open Access 01.12.2023 | Research

Effect of annualized surgeon volume on major surgical complications for abdominal and laparoscopic radical hysterectomy for cervical cancer in China, 2004–2016: a retrospective cohort study

verfasst von: Cong Liang, Weili Li, Xiaoyun Liu, Hongwei Zhao, Lu Yin, Mingwei Li, Yu Guo, Jinghe Lang, Xiaonong Bin, Ping Liu, Chunlin Chen

Erschienen in: BMC Women's Health | Ausgabe 1/2023

Abstract

Background

Previous studies have suggested that higher surgeon volume leads to improved perioperative outcomes for oncologic surgery; however, the effect of surgeon volumes on surgical outcomes might differ according to the surgical approach used. This paper attempts to evaluate the effect of surgeon volume on complications or cervical cancer in an abdominal radical hysterectomy (ARH) cohort and laparoscopic radical hysterectomy (LRH) cohort.

Methods

We conducted a population-based retrospective study using the Major Surgical Complications of Cervical Cancer in China (MSCCCC) database to analyse patients who underwent radical hysterectomy (RH) from 2004 to 2016 at 42 hospitals. We estimated the annualized surgeon volumes in the ARH cohort and in the LRH cohort separately. The effect of the surgeon volume of ARH or LRH on surgical complications was examined using multivariable logistic regression models.

Results

In total, 22,684 patients who underwent RH for cervical cancer were identified. In the abdominal surgery cohort, the mean surgeon case volume increased from 2004 to 2013 (3.5 to 8.7 cases) and then decreased from 2013 to 2016 (8.7 to 4.9 cases). The mean surgeon case volume number of surgeons performing LRH increased from 1 to 12.1 cases between 2004 and 2016 (P < 0.01). In the abdominal surgery cohort, patients treated by intermediate-volume surgeons were more likely to experience postoperative complications (OR = 1.55, 95% CI = 1.11–2.15) than those treated by high-volume surgeons. In the laparoscopic surgery cohort, surgeon volume did not appear to influence the incidence of intraoperative or postoperative complications (P = 0.46; P = 0.13).

Conclusions

The performance of ARH by intermediate-volume surgeons is associated with an increased risk of postoperative complications. However, surgeon volume may have no effect on intraoperative or postoperative complications after LRH.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1186/​s12905-023-02213-6.
Cong Liang, Weili Li, Xiaoyun Liu and Hongwei Zhao have contributed equally to the manuscript.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Cervical cancer ranks fourth among the most frequently diagnosed cancer in women (570,000 cases) [1], and radical hysterectomy (RH) with bilateral pelvic lymph node dissection is the recommended surgical treatment for women with early-stage disease [2]. The guidelines from the National Comprehensive Cancer Network (NCCN), International Federation of Gynecology and Obstetrics (FIGO) and National Institute for Health and Care Excellence (NICE) state that “the standard approach for RH is with an open abdominal approach” [24]. Although patient-related factors and clinical factors, such as obesity, diabetes, FIGO stage, the lack of standard medical care, surgical approach and hospital volume, are known to influence major complications during RH, there is growing recognition that surgeon volume also affects the outcomes for RH [58].
Regarding cervical cancer, the current engagement literature is focused mostly on the effects of hospital volume on clinical outcomes, with less attention given to the effects of surgeon volume on perioperative outcomes. For patients with early-stage cervical cancer, surgery at high-volume centres is associated with lower reduced perioperative morbidity and improved survival, whereas for patients with locally advanced disease, hospital volume has a minimal impact on survival [911]. In addition to resources available at the hospital, the outcome of a surgical procedure may depend mainly on surgeon volume [12]. Accumulative evidence to date has suggested that higher surgeon volume leads to improved perioperative surgical outcomes for various cancer, such as oesophageal cancer, brain tumours, pancreatic cancer, bladder cancer, endometrial cancer, rectal cancer and lung cancer [1319]. However, some scholars argue that surgeon volume is not associated with complications [20, 21]. Recognition of the volume-outcomes paradigm in high-risk cancer procedures has led to changes in practice. Consequently, some health systems are instituting a minimum surgeon volume standard for high-risk surgery, such as oesophagectomy [19]. Wright et al. demonstrated that women treated by high-volume surgeons had fewer postoperative medical complications and lower transfusion requirements after abdominal RH (ARH) [22]. To date, few studies have investigated the association between surgeon volume and outcomes of RH in a cohort of abdominal cases and laparoscopic cases, respectively. In addition, there is a paucity of data on surgeon volume in Asian populations.
The objective of this population-based analysis is to explore the association between annualized surgeon volume and complications in an ARH cohort and a laparoscopic radical hysterectomy (LRH) cohort, respectively.

Methods

Data source

Data from the Major Surgical Complications of Cervical Cancer in China (MSCCCC) project database were utilized. The MSCCCC database is a multicentre retrospective database established to measure surgical quality. Approximately 97.5% of cases from the database could be matched to the cases in the Chinese Clinical Cervical Cancer (FOUR-C) project (http://​www.​chictr.​org.​cn/​index.​aspx, ChiCTR1800017778). The MSCCCC database gathers hospitalization information for 36,543 patients from 42 hospitals in 14 provinces of China from 2004 to 2016 (updated June 2020). The 42 hospitals consist of 32 general hospitals, 4 cancer centres and 6 women and children’s hospitals (W&C hospitals) [23].
By using the discharge diagnosis of “cervical cancer” as the keyword or the International Classification of Diseases Tenth Revision code C53.9 for computerized search, specially-trained gynaecologists abstracted data from medical records and the hospital information system. The documentation used for data extraction on complications included inpatient medical records for surgical treatment, postoperative adjuvant therapy records within 6 months, outpatient records, and readmission to the another department for complication treatment within 2 years [23]. The MSCCCC database collects data on patient demographics, clinical characteristics, and hospital factors. After completion of double data entry, data checking was carried out by two independent gynaecologists to eliminate input errors and logic errors. Data masking was used to protect patient privacy. Ethical approval was obtained from the Institutional Ethics Committee of Southern Medical University Nanfang Hospital (NFEC-2017–135).

Cohort identification

Women who underwent RH for cervical cancer between 2004 and 2016 were analysed. The inclusion criteria were as follows: (1) the patient had been diagnosed with stage IA1 with LVSI (lymphovascular space invasion) to stage IIB disease, according to the 2009 FIGO staging system; (2) the patient had undergone type B or C RH (Querleu and Morrow classification) [24] + pelvic lymphadenectomy (PLN) ± para-aortic lymphadenectomy (PALA); and (3) the patient had undergone ARH or LRH. RH is mentioned as a treatment option for stage IIB disease in the Japan Society of Gynaecologic Oncology guidelines 2017 [25]. Chemoradiotherapy and neoadjuvant chemotherapy (NACT) followed by RH are recommended for patients with stage IIB cervical cancer in the European guidelines [26]. As such, we also included patients with FIGO stage IIB.
The exclusion criteria were as follows: (1) the patient was diagnosed with cervical cancer during pregnancy, was diagnosed with incidental cervical cancer after extrafascial hysterectomy or had a prior history of other malignancies; (2) the patient had an unknown lymphadenectomy status or did not undergo lymphadenectomy; (3) the patient underwent laparoscopic-assisted radical vaginal hysterectomy or robot-assisted RH; or (4) the patient had missing surgeon data or a missing date of operation.

Clinical and demographic characteristics

The demographic characteristics included age, year of surgery, urban‒rural distribution, mode of delivery, and comorbidities. Clinical characteristics that were analysed included FIGO stage, gross type of tumour, histological type, preoperative anticancer treatment, hysterectomy type and lymph node dissection. Other operation details included operative time and estimated blood loss.
The hospitals where patients were treated were characterized based on hospital function (general hospital, cancer centre, or W&C hospital), region of the country (north, south, central, east, southwest, northwest or northeast), and city scale (first-tier, second-tier, and third-tier or below). The levels of urban economic development were as follows: first-tier cities > second-tier cities > third-tier cities.

Surgeon volume

Surgeons were sequentially numbered. Then we calculated the total volume for each surgeon, and the annualized surgeon volumes was calculated as the total number of procedures that the surgeon performed divided by the number of years in which an individual surgeon contributed to at least one RH [17, 22, 27]. Patients were stratified into two cohorts based on the hysterectomy approach: ARH group or LRH group. Surgeon volume cut-off points were then selected to divide patients into approximately equal tertiles. Abdominal surgeon cut-off points were as follows: low volume (≤ 8.1 procedures per year), intermediate volume (8.2–16.9 procedures per year), and high volume (> 16.9 procedures per year). Laparoscopic surgeon cut-off points were: low volume (≤ 11.0 procedures per year), intermediate volume (11.1–20.0 procedures per year), and high volume (> 20.0 procedures per year).

Outcomes

Complications were divided into intraoperative complications and postoperative complications. Intraoperative complications, which included ureteral injury, bladder injury, bowel injury, vascular injury, obturator nerve injury, and stomach injury, were recorded. Postoperative complications included bowel obstruction, pelvic haematoma, haemorrhage, vesicovaginal fistula, ureterovaginal fistula, ureteral fistula, rectovaginal fistula, venous thromboembolism and chylous leakage. We also recorded deaths from surgical complications.

Statistical analysis

The relationship between the number of surgeons and year was assessed by a nonparametric Spearman correlation test. Due to discontinuous data, one of the hospitals was not included in the graphs. Frequency distributions between categorical variables were compared using χ2 (Bonferroni corrected, if required) or Fisher’s exact test, and continuous variables were compared using one-way analysis of variance. The median and interquartile range (IQR) of surgeon volume were also reported for each tertile. Binary logistic regression models were used to determine predictors of treatment by the intermediate and high volume (highest 2/3 volume) surgeons. Demographic, clinical, and hospital characteristics constituted independent variables. To examine the association between surgeon volume and outcome, we built binary logistic regression models including surgeon volume while adjusting for the other variables described above. The results are reported as odds ratios (ORs) and 95% confidence intervals (CIs). A value of P < 0.05 was considered statistically significant. All analyses were performed with the SPSS 23.0 statistical software package (SPSS, Inc., Chicago, IL, USA).

Results

We identified a total of 22,684 patients, including 14,536 (64.1%) patients who underwent ARH and 8148 (35.9%) patients who underwent LRH (Table 1). The number of surgeons performing ARH each year increased from 89 surgeons who operated on 313 patients in 2004 to 187 surgeons who operated on 1,294 patients in 2012 (P < 0.01, r = 0.99). However, the number of abdominal surgeons decreased to 122 surgeons with 594 patients in 2016 (P = 0.20, r = − 0.80). The mean surgeon case volume increased from 3.5 cases in 2004 to 8.7 cases in 2013 and then decreased to 4.9 cases in 2016 (Fig. 1A). The number of surgeons performing LRH increased from 1 surgeon with 1 patient in 2004 to 183 surgeons who operated on 2,206 patients in 2016 (P < 0.01, r = 0.99). The mean number of surgeons performing LRH increased from 1 to 12.1 cases between 2004 and 2016 (Fig. 1B).
Table 1
Schema of patient selection
Variable
No. of patients
1.All patients diagnosed with cervical cancers, 2004–2016
36,543
2. Type B or C radical hysterectomy
31,581
3. Pelvic lymphadenectomy ± para-aortic lymphadenectomy
30,641
4. 2009 FIGO stage IA1 with LVSI to IIB
24,447
5. No pregnancy, incidental cervical cancer or previous malignant disease
24,350
6. Abdominal surgery or total laparoscopic surgery
23,409
7. Missing information of surgeon or date of surgery
22,684

Characteristics of the cohort

In the ARH cohort, the median volume of surgeons in the low-volume group was two (IQR 1.0–3.5) per year and rose to 30.9 (IQR 21.9–42.1) in the high volume group. Similarly, in the LRH cohort, the median volume of surgeons in the low-volume group was 2.3 (IQR 1.0–5.0) and increased to 27.8 (IQR 21.6–30.1) in the high-volume group (Table 2). In both the ARH and LRH cohorts, the operation time and bleeding loss for patients in the high-volume surgeon group were significantly lower than those for patients in the intermediate-volume and low-volume groups (P < 0.001) (Table 2).
Table 2
Demographic and clinical characteristics of the abdominal and laparoscopic cohorts stratified by surgeon volume
Characteristic
Abdominal surgeon volume
P value
Laparoscopic surgeon volume
P value
Low
Intermediate
High
Low
Intermediate
High
Patients
4837
33.3
4913
33.8
4786
32.9
 
2642
32.4
2637
32.4
2869
35.2
 
Surgeons
361
 
44
 
22
  
212
 
33
 
18
  
Annualized hospital volume
2.0 (1.0–3.5)
10.8 (9.1–12.5)
30.9 (21.9–42.1)
 
2.3 (1.0–5.0)
13.5 (12.3–16.9)
27.8 (21.6–30.1)
 
Range
1.0
8.1
8.2
16.9
17.0
129.4
 
1.0
11.0
11.1
20.0
20.1
51.7
 
Age at surgery, years
 ≥ 60
444
9.2
515
10.5
798
16.7
 < 0.001
257
9.7
299
11.3
346
12.1
0.02
 < 60
4393
90.8
4398
89.5
3988
83.3
 
2385
90.3
2338
88.7
2523
87.9
 
Year of diagnosis
2004–2009
1736
35.9
1748
35.6
245
5.1
 < 0.001
149
5.6
46
1.7
59
2.1
 < 0.001
2010–2016
3101
64.1
3165
64.4
4541
94.9
 
2493
94.4
2591
98.3
2810
97.9
 
Urban‒rural distribution
Rural
2316
47.9
2988
60.8
3098
64.7
 < 0.001
1572
59.5
1450
55.0
1638
57.1
 < 0.001
Urban
1423
29.4
1539
31.3
1004
21.0
 
739
28.0
959
36.4
1055
36.8
 
Unknown
1098
22.7
386
7.9
684
14.3
 
331
12.5
228
8.6
176
6.1
 
Hospital function
General hospital
3451
71.3
2893
58.9
641
13.4
 < 0.001
1998
75.7
2097
79.5
1526
53.2
 < 0.001
Cancer centre
1088
22.5
1626
33.1
4145
86.6
 
450
17.0
386
14.6
1223
42.6
 
W&C centre
298
6.2
394
8.0
0
0.0
 
194
7.3
154
5.8
120
4.2
 
Region
North
724
15.0
1292
26.3
2784
58.2
 < 0.001
589
22.3
220
8.3
605
21.1
 < 0.001
South
1380
28.5
1095
22.3
531
11.1
 
688
26.1
427
16.2
120
4.2
 
Central
618
12.8
410
8.3
1169
24.4
 
350
13.2
700
26.5
231
8.1
 
East
1490
30.8
1013
20.6
302
6.3
 
752
28.5
396
15.0
0
0.0
 
Southwest
307
6.3
335
6.8
0
0.0
 
91
3.4
507
19.2
1808
63.0
 
Northwest
158
3.3
668
13.6
0
0.0
 
161
6.1
323
12.2
105
3.7
 
Northeast
160
3.3
100
2.0
0
0.0
 
11
0.4
64
2.4
0
0.0
 
City scale
First-tier
773
16.0
745
15.2
529
11.1
 < 0.001
560
21.2
299
11.3
0
0.0
 < 0.001
Second-tier
2458
50.8
2885
58.7
3986
83.3
 
1471
55.7
1916
72.7
2362
82.3
 
Third-tier
1606
33.2
1283
26.1
271
5.7
 
611
23.1
422
16.0
507
17.7
 
Mode of delivery
No delivery
49
1.0
57
1.2
22
0.5
 < 0.001
23
0.9
23
0.9
36
1.3
 < 0.001
Vaginal delivery
3684
76.2
4026
81.9
4059
84.8
 
2114
80.0
2157
81.8
2541
88.6
 
Caesarean delivery
253
5.2
291
5.9
221
4.6
 
194
7.3
243
9.2
261
9.1
 
Unknown
851
17.6
539
11.0
484
10.1
 
311
11.8
214
8.1
31
1.1
 
Comorbidity
No
4526
93.6
4592
93.5
4242
88.6
 < 0.001
2425
91.8
2436
92.4
2611
91.0
0.18
Yes
311
6.4
321
6.5
544
11.4
 
217
8.2
201
7.6
258
9.0
 
FIGO stage
IA1 + IA2
133
2.7
76
1.5
30
0.6
 < 0.001
70
2.7
49
1.9
45
1.6
 < 0.001
IB1
2288
47.3
2117
43.1
2282
47.7
 
1554
58.8
1323
50.2
1318
45.9
 
IB2
656
13.6
690
14.0
531
11.1
 
289
10.9
295
11.2
328
11.4
 
IIA1
679
14.0
680
13.8
1278
26.7
 
350
13.2
329
12.5
586
20.4
 
IIA2
297
6.1
324
6.6
478
10.0
 
123
4.7
176
6.7
270
9.4
 
IIB
784
16.2
1026
20.9
187
3.9
 
256
9.7
465
17.6
322
11.2
 
Gross type
Exophytic
2585
53.4
2854
58.1
2058
43.0
 < 0.001
1287
48.7
1357
51.5
1540
53.7
 < 0.001
Endophytic
276
5.7
316
6.4
1528
31.9
 
128
4.8
73
2.8
185
6.4
 
Ulcerated
900
18.6
790
16.1
550
11.5
 
461
17.4
467
17.7
699
24.4
 
Endocervical
105
2.2
64
1.3
29
0.6
 
45
1.7
39
1.5
44
1.5
 
After conization
132
2.7
106
2.2
74
1.5
 
80
3.0
97
3.7
102
3.6
 
Preclinical carcinoma
342
7.1
414
8.4
178
3.7
 
298
11.3
256
9.7
140
4.9
 
Unknown
497
10.3
369
7.5
369
7.7
 
343
13.0
348
13.2
159
5.5
 
Histological types
Squamous cell
4178
86.4
4326
88.1
4301
89.9
 < 0.001
2252
85.2
2223
84.3
2481
86.5
0.008
Adenocarcinoma
450
9.3
397
8.1
294
6.1
 
262
9.9
293
11.1
272
9.5
 
Adenosquamous
113
2.3
92
1.9
94
2.0
 
45
1.7
54
2.0
49
1.7
 
Other subtypes
81
1.7
90
1.8
89
1.9
 
48
1.8
43
1.6
56
2.0
 
Unknown
15
0.3
8
0.2
8
0.2
 
35
1.3
24
0.9
11
0.4
 
Preoperative treatment
No received
3457
71.5
3565
72.6
3911
81.7
 < 0.001
2038
77.1
2098
79.6
2164
75.4
 < 0.001
Neoadjuvant chemotherapy
1243
25.7
970
19.7
594
12.4
 
557
21.1
449
17.0
667
23.2
 
Preoperative radiotherapy
137
2.8
378
7.7
281
5.9
 
47
1.8
90
3.4
38
1.3
 
Lymph node dissection
PLA
4651
96.2
4604
93.7
4735
98.9
 < 0.001
2269
85.9
2028
76.9
1905
66.4
 < 0.001
PLA + PALA
186
3.8
309
6.3
51
1.1
 
373
14.1
609
23.1
964
33.6
 
Hysterectomy types
              
Type B
2852
59.0
2140
43.6
3340
69.8
 < 0.001
1047
39.6
592
22.4
242
8.4
 < 0.001
Type C2
1962
40.6
2719
55.3
1424
29.7
 
1558
59.0
1991
75.5
2616
91.2
 
Type C1
23
0.5
54
1.1
22
0.5
 
37
1.4
54
2.0
11
0.4
 
Operation time (min)
232.8 ± 64.8
 
205.0 ± 55.4
 
164.7 ± 52.8
 
 < 0.001
259.6 ± 77.1
 
234.4 ± 70.8
 
209.6 ± 64.6
 
 < 0.001
Blood loss (ml)
499.2 ± 363.1
 
470.3 ± 375.14
 
241.0 ± 211.6
 
 < 0.001
216.2 ± 305.7
 
193.0 ± 188.6
 
185.1 ± 170.1
 
 < 0.001
PLA pelvic lymphadenectomy, PALA para-aortic lymphadenectomy
In the multivariable model of the ARH cohort, patients diagnosed in later years, patients living in rural areas, patients with a higher tumour stage (except stage IIB), patients with the endophytic or preclinical gross type, patients with preoperative radiotherapy, patients undergoing type C1 or C2 hysterectomy, patients undergoing surgery in a W&C hospital or cancer centre, and patients undergoing surgery in a hospital of a first-tier city were more likely to be treated by high-volume or intermediate-volume surgeons (P < 0.05) (Table 3).
Table 3
Predictors of high- and intermediate-volume surgeons
 
Abdominal cohort
Laparoscopic cohort
OR (95% CI)
P value
OR (95% CI)
P value
Age at surgery, years
 
0.15
 
0.002
 ≥ 60
Ref
 
Ref
 
 < 60
0.91 (0.79–1.04)
0.15
0.74 (0.61–0.90)
0.002
Year of diagnosis
 
 < 0.001
 
0.02
2004–2009
Ref
 
Ref
 
2010–2016
1.55 (1.41–1.69)
 < 0.001
1.47 (1.07–2.02)
0.02
Urban–rural distribution
 
 < 0.001
 
0.08
Rural
Ref
 
Ref
 
Urban
0.87 (0.80–0.96)
0.005
1.11 (0.97–1.27)
0.13
Unknown
0.51 (0.45–0.58)
 < 0.001
0.87 (0.71–1.07)
0.20
Hospital function
 
 < 0.001
 
 < 0.001
General hospital
Ref
 
Ref
 
Cancer center
3.45 (3.07–3.87)
 < 0.001
1.83 (1.49–2.24)
 < 0.001
W&C center
1.55 (1.27–1.89)
 < 0.001
0.26 (0.20 -0.35)
 < 0.001
Region
 
 < 0.001
 
 < 0.001
North
Ref
 
Ref
 
South
0.45 (0.38–0.54)
 < 0.001
4.91 (3.66–6.59)
 < 0.001
Central
0.91 (0.78–1.06)
0.23
2.12 (1.68–2.68)
 < 0.001
East
0.37 (0.32–0.42)
 < 0.001
0.36 (0.28–0.45)
 < 0.001
Southwest
1.05 (0.84–1.31)
0.70
82.00 (57.57–116.82)
 < 0.001
Northwest
3.31 (2.56–4.28)
 < 0.001
1.29 (0.88–1.88)
0.19
Northeast
0.22 (0.16–0.29)
 < 0.001
3.36 (1.71–6.59)
 < 0.001
City scale
 
 < 0.001
 
 < 0.001
First-tier
Ref
 
Ref
 
Second-tier
0.70 (0.59–0.85)
 < 0.001
8.74 (6.31–12.10)
 < 0.001
Third-tier
0.36 (0.31–0.43)
 < 0.001
1.18 (0.89–1.56)
0.26
Mode of delivery
 
 < 0.001
 
0.004
No delivery
1.00 (0.68–1.48)
0.99
1.06 (0.57–1.97)
0.85
Vaginal delivery
Ref
 
Ref
 
Cesarean delivery
1.06 (0.89–1.27)
0.54
1.35 (1.10–1.68)
0.005
Unknown
0.66 (0.59–0.74)
 < 0.001
1.34 (1.07–1.67)
0.01
Comorbidity
 
0.41
 
0.43
No
Ref
 
Ref
 
Yes
0.93 (0.79–1.10)
0.41
1.09 (0.88–1.35)
0.43
FIGO stage
 
 < 0.001
 
 < 0.001
IA + IB1
Ref
 
Ref
 
IB2
1.08 (0.94–1.23)
0.28
1.26 (1.02–1.57)
0.03
IIA1
1.28 (1.13–1.44)
 < 0.001
1.23 (1.02–1.48)
0.02
IIA2
1.28 (1.07–1.52)
0.006
2.26 (1.70–3.01)
 < 0.001
IIB
0.75 (0.63–0.88)
 < 0.001
1.60 (1.20–2.14)
0.002
Gross type
 
 < 0.001
 
0.009
Exophytic
Ref
 
Ref
 
Endophytic
2.09 (1.78–2.45)
 < 0.001
0.64 (0.48–0.86)
0.003
Ulcerated
0.87 (0.78–0.98)
0.02
1.16 (0.99–1.38)
0.08
Endocervical
0.56 (0.40–0.77)
 < 0.001
0.89 (0.56–1.42)
0.62
After conization
0.85 (0.66–1.10)
0.23
1.17 (0.84–1.65)
0.35
Preclinical carcinoma
1.39 (1.19–1.63)
 < 0.001
0.88 (0.72–1.08)
0.22
Unknown
0.70 (0.61–0.81)
 < 0.001
1.04 (0.86–1.26)
0.71
Histological types
 
0.021
 
0.96
Squamous cell
Ref
 
Ref
 
Adenocarcinoma
0.89 (0.77–1.03)
0.18
1.06 (0.87–1.29)
0.54
Adenosquamous
0.82 (0.62–1.07)
0.15
1.00 (0.65–1.56)
0.97
Other subtypes
0.66 (0.49–0.90)
0.008
0.98 (0.64–1.48)
0.91
Unknown
0.70 (0.31–1.60)
0.40
0.88 (0.50–1.57)
0.66
Preoperative treatment
 
 < 0.001
 
 < 0.001
No received
Ref
 
Ref
 
Neoadjuvant chemotherapy
0.81 (0.72–0.91)
0.001
0.69 (0.57–0.82)
 < 0.001
Preoperative radiotherapy
1.92 (1.53–2.40)
 < 0.001
0.85 (0.58–1.26)
0.42
Lymph node dissection
 
0.98
 
0.04
PLA
Ref
 
Ref
 
PLA + PALA
1.00 (0.81–1.23)
0.98
1.19 (1.01–1.40)
0.04
Hysterectomy types
 
 < 0.001
 
 < 0.001
Type B
Ref
 
Ref
 
Type C2
1.75 (1.59–1.93)
 < 0.001
2.33 (1.98–2.75)
 < 0.001
Type C1
2.73 (1.61–4.64)
 < 0.001
3.60 (2.27–5.72)
 < 0.001
PLA pelvic lymphadenectomy, PALA para-aortic lymphadenectomy
Similarly, in the multivariable model of the LRH cohort, age > 60 years, later year of diagnosis, previous caesarean section, FIGO stage IIA2 or IIB, PLN + PALA, and type C1 or C2 hysterectomy were associated with treatment by a high-volume or an intermediate-volume surgeon (P < 0.05). In addition, patients undergoing surgery in the cancer centre, patients undergoing surgery in the hospital of a second-tier city, and patients undergoing surgery in the hospital of the southwest area were more likely to be treated by intermediate- or high-volume surgeons (P < 0.05). Patients with the endophytic gross type, patients with neoadjuvant chemotherapy, and patients undergoing surgery in W&C hospitals were associated with treatment by a low-volume laparoscopic surgeon (P < 0.05) (Table 3).

The impact of surgeon volume on complications

In the univariate analysis of the ARH group, the overall complication rates were 3.06% for women treated by low-volume surgeons, 3.42% for those treated by intermediate-volume surgeons, and 2.01% for those treated by high-volume surgeons (P < 0.001) (Table 4). Compared with patients treated by intermediate-volume surgeons, those operated on by high-volume surgeons had fewer postoperative complications (2.87% vs. 1.69%, P < 0.001), fewer ureteral injuries (0.45% vs. 0.16%, P = 0.045), fewer bowel obstructions (1.28% vs. 0.61%, P = 0.003), and fewer ureterovaginal fistulas (0.43% vs. 0.13%, P = 0.007). There were no significant differences in the frequencies of other complications (P < 0.05).
Table 4
Unadjusted complications associated with radical hysterectomy for cervical cancer stratified by surgeon volume
Outcome
Abdominal surgeon volume
P value
Laparoscopic surgeon volume
P value
Low
Intermediate
High
Low
Intermediate
 
High
N
%
N
%
N
%
N
%
N
%
N
%
Any 1 complication
148
3.06a
168
3.42a
96
2.01b
 < 0.001
137
5.19
150
5.69
148
5.16
0.62
Intraoperative complication
27
0.56
32
0.65
16
0.33
0.08
39
1.48
24
0.91
44
1.53
0.09
Ureteral injury
15
0.31ab
22
0.45a
8
0.16b
0.045
28
1.06
14
0.53
24
0.84
0.10
Bladder injury
3
0.06
4
0.08
1
0.02
0.55
3
0.11
4
0.15
8
0.28
0.34
Bowel injury
0
0
2
0.04
0
0
0.33
1
0.04
1
0.04
4
0.14
0.38
Vascular injury
9
0.18
2
0.04
5
0.10
0.10
4
0.15
4
0.15
7
0.24
0.69
Obturator nerve injury
0
0
2
0.04
2
0.04
0.48
5
0.19
1
0.04
2
0.07
0.24
Stomach injury
0
0
0
0
0
1
0.04
0
0
0
0
0.65
Postoperative complication
122
2.52a
141
2.87a
81
1.69b
 < 0.001
102
3.86
127
4.81
110
3.83
0.12
Bowel obstruction
46
0.95ab
63
1.28a
29
0.61b
0.003
18
0.68
18
0.68
21
0.73
0.97
Pelvic hematoma
1
0.02
1
0.02
0
0
0.99
0
0
2
0.08
0
0
0.11
Hemorrhage
3
0.06
3
0.06
1
0.02
0.71
5
0.19
3
0.11
5
0.17
0.83
Vesicovaginal fistula
8
0.16
9
0.18
6
0.13
0.81
19
0.72
17
0.64
24
0.84
0.71
Ureterovaginal fistula
9
0.19ab
21
0.43a
6
0.13b
0.007
27
1.02a
47
1.78b
31
1.08a
0.02
Rectovaginal fistula
1
0.02
2
0.04
1
0.02
0.99
3
0.11
3
0.11
3
0.10
0.99
Ureteral fistula
3
0.06
3
0.06
1
0.02
0.71
4
0.15
2
0.08
2
0.07
0.67
Venous thromboembolism
51
1.05
43
0.88
37
0.77
0.34
28
1.06
38
1.44
24
0.84
0.10
Chylous leakage
1
0.02
0
0
0
0
0.66
3
0.11
5
0.19
3
0.10
0.69
Other
              
Death
0
0
0
0
2
0.04
0.11
0
0
1
0.04
1
0.03
0.77
Different letters on the shoulder mark indicate significant differences (P < 0.05), and the same letter or no letter indicates that the difference is not significant (P ≥ 0.05)
In the univariate analysis of the LRH group, patients treated by intermediate-volume surgeons had the highest ureterovaginal fistula rate (low vs. intermediate vs. high volume = 1.02% vs. 1.78% vs. 1.08%, P = 0.02). The frequencies of the other complications among laparoscopic surgery cases were similar across the three groups (P > 0.05) (Table 4).
In the multivariable analysis of the ARH cohort, patients treated by intermediate-volume surgeons were more likely to experience postoperative complications (OR = 1.55, 95% CI = 1.11–2.15), especially bowel obstruction (OR = 1.75, 95% CI = 1.05–2.94) and ureterovaginal fistula (OR = 3.47, 95% CI = 1.27–9.53), than those treated by high-volume surgeons (Table 5; Additional file 1: Table S1). The postoperative complication rate was higher in the low-volume surgeon group than in the high-volume surgeon group, and the difference approached significance (OR = 1.38, 95% CI = 0.97–1.96, P = 0.07). However, abdominal surgeon volume had no influence on overall complications or intraoperative complications (P > 0.05). In the multivariable analysis of the LRH cohort, surgeon volume had no effect on overall complications, intraoperative complications or postoperative complications (P > 0.05).
Table 5
Multivariable analysis of factors associated with complications
 
Abdominal surgeon volume
P value
Laparoscopic surgeon volume
P value
 
Low
Intermediate
High
 
Low
intermediate
High
 
Any 1 complication
3.06%
3.42%
2.01%
 
0.10
5.19%
5.69%
5.16%
 
0.26
   
1.20
0.87–1.66
0.27
  
1.14
0.82–1.58
0.43
   
1.39
1.02–1.89
0.04
  
1.26
0.95–1.67
0.11
Intraoperative complication
0.56%
0.65%
0.33%
 
0.21
1.48%
0.91%
1.53%
 
0.46
   
0.46
0.19–1.09
0.08
  
1.23
0.67–2.26
0.51
   
0.58
0.25–1.38
0.22
  
0.86
0.48–1.54
0.61
Postoperative complication
2.52%
2.87%
1.69%
 
0.04
3.86%
4.81%
3.83%
 
0.13
   
1.38
0.97–1.96
0.07
  
1.09
0.75–1.58
0.65
   
1.55
1.11–2.15
0.01
  
1.34
0.98–1.83
0.07
The middle row for each complication class was adjusted for clinical and demographic factors, including age, year of diagnosis, urban–rural distribution, hospital function, region, city scale, mode of delivery, comorbidity, FIGO stage, gross type, histological type, preoperative treatment, lymph node dissection, and hysterectomy type reported, with the odds ratio (95% CI) of low vs. high volume. The bottom row for each complication class is adjusted for the factors mentioned above, with the odds ratio (95% CI) of intermediate vs. high volume

Discussion

Our findings suggest that in the ARH cohort, postoperative complication rates were higher among intermediate-volume surgeons, while patients treated by high-volume surgeons had fewer postoperative complications. However, in the LRH cohort, annualized surgeon volume had no effect on intraoperative or postoperative complications.
The trends in the number of surgeons and mean surgeon volume over time differed between the two surgical approaches. From 2004 to 2016, the number of laparoscopic surgeons and mean surgeon case volume rose annually. This increasing acceptance of the laparoscopic technique could be due to the short-term benefits of LRH, including a more cosmetically pleasing incision, less bleeding, less postoperative pain, and faster postoperative recovery. However, the opposite trend was observed in the ARH cohort. The number of abdominal surgeons and mean surgeon case volume had been decreasing since 2013. In addition, it is noteworthy that categorical definitions of surgeon volume varied substantially among the different studies. In the study by Wright et al. [22], a high-volume surgeon and a low-volume surgeon were defined as a surgeon who performed more than 3.75 and less than 2.25 ARHs per year, respectively, but our definitions of high volume and low volume were greater than 16.9 and less than or equal to 8.1 ARHs per year, respectively. The surgeon volume gap between the two groups was much larger than that of the study by Wright et al. In addition, our results revealed a positive correlation between the number of surgeons and the number of patients. The increasing number of surgeons could effectively alleviate disease stress at the national level; however, additional investigations are needed to determine whether the regionalization of RH is occurring in China. Spontaneous regionalization of gynaecological malignancy procedures has occurred in the US. At the hospital level, Matsuo et al.’s analysis showed that 89 centres that performed at least one trachelectomy for cervical cancer per year and only 6 centres met the criteria for top-decile centres in the United States [9]. The threshold of any RH to have a minimum trachelectomy volume of 1 case a year was 7.8 cases per year. These findings imply that trachelectomy may have already been regionalized to hospitals with high RH volumes. At the surgeon level, the surgical treatment of an increasing number of patients with endometrial cancer has been limited to a smaller number of surgeons. The increased complexity of treatment has resulted in more patients being referred from general gynaecologists to gynaecologic oncology subspecialists [17].
Our data demonstrated that the association between surgeon volume and complications for cervical cancer was complex with an increased risk of postoperative complications among intermediate-volume surgeons but the lowest postoperative complication rates for the highest-volume surgeons in the ARH cohort. In the multivariable analysis of the ARH cohort, patients treated by intermediate-volume surgeons were more likely to experience postoperative complications (OR = 1.55, 95% CI = 1.11–2.15), especially bowel obstruction (OR = 1.75, 95% CI = 1.05–2.94) and ureterovaginal fistula (OR = 3.47, 95% CI = 1.27–9.53), than those treated by high-volume surgeons. In addition, the postoperative complication rate was higher in the low-volume surgeon group than in the high-volume surgeon group, and the difference approached significance (OR = 1.38, 95% CI = 0.97–1.96, P = 0.07). This observation resembles that of Wright et al. [22]. Their results showed that the perioperative complication rate was highest in the intermediate-volume surgeon group compared with the low-volume and high-volume surgeon groups (low vs. intermediate vs. high = 2.9% vs. 6.7% vs. 1.8%, P < 0.001). Additionally, compared with patients treated by low-volume surgeons, those operated on by high-volume surgeons had fewer medical complications and shorter lengths of stay [22]. However, no direct comparisons between the intermediate-volume surgeon group and other groups were performed in their study. Another study evaluating the influence of surgeon volume on morbidity with regard to hysterectomy reached the similar conclusions: outcomes are significantly worse among low-volume surgeons than among higher-volume surgeons for abdominal hysterectomy [28]. The majority of high-volume surgeons benefited from the effect of a sufficient learning curve and close cooperation with an experienced surgical team, which translates into a lower complication rate. One possible reason for the intermediate-volume surgeon group having the highest rate of postoperative complications could be that they were more lenient in their selection of patients. Patients treated by intermediate-volume surgeons had a higher frequency of FIGO stage IIB, more preoperative radiotherapy, and a higher frequency of PLA + PALA and type C2 hysterectomy. In the Laparoscopic Approach to Cervical Cancer (LACC) trial, ARH was associated with higher disease-free survival and overall survival rates than minimally invasive RH among women with early-stage cervical cancer [29]. The publication of the results of the LACC trial led to important changes in the management of cervical cancer patients worldwide [30]. After this publication, the number of patients treated with minimally invasive RH decreased from 64.9% to 30.4% [31]. ARH therefore has re-emerged as a mainstream treatment for cervical cancer, bringing attention to the effect of abdominal surgeon volume on the complication rates.
Despite the finding of poor survival with minimally invasive surgery (MIS) in LACC trail, some studies were still conducted to re-establish the role of MIS and select the appropriate patient for MIS, considering the tumour size and the histological type [3235]. Thus, further exploration of the effect of surgeon volume on complications among patients who undergo LRH is also warranted. In our laparoscopy surgery cohort, surgeon volume had no significant effects on intraoperative complications or postoperative complications. It appears that the effects of surgeon volume on RH complications differ according to the surgical routes used. Similar results of endometrial cancer have reported that among patients who underwent abdominal hysterectomy for endometrial cancer, increased surgical volume was associated with reductions in perioperative surgical complications and medical complications [36]. However, during laparoscopic hysterectomy, the surgeon volume appeared to have little effect on perioperative morbidity for endometrial cancer [27]. A retrospective analysis of 1016 laparoscopic hysterectomies for benign gynaecologic problems found that increasing the surgical volume could not reduce the rate of serious complications [37]. The population-based study by Ruiz et al. demonstrated that the comparative safety of abdominal and laparoscopic hysterectomy was influenced by surgeon volume, but that the volume-outcomes relationship was not present in robotic-assisted or vaginal hysterectomy [28].
Interestingly, in ARH cohort, patients with stage IIB were less likely to be treated by high-volume or intermediate-volume surgeons. However, in LRH cohort, stage IIB disease was more frequently seen by high-volume or intermediate-volume surgeons than by low-volume surgeons. A possible explanation for this might be different guideline compliance rates in different kinds of hospitals. In the ARH cohort, 59.5% of patients treated by high-volume or intermediate-volume surgeons received treatment from a cancer centre, whereas in the LRH cohort, only 29.2% of patients treated by high-volume or intermediate-volume surgeons received treatment from cancer centre (Additional file 1: Table S2). This might be related to higher compliance with stage IIB treatment guidelines in cancer centres. Matsuo et al. had similar findings in their assessment of hospital volume. Matsuo et al. examined 5,964 women with cervical cancer who underwent RH (mostly ARH) and found that stage IIB disease was less frequently seen in the high-surgical volume group than in the other groups [10]. In our study, patients treated by high-volume or intermediate-volume surgeons were less likely to receive neoadjuvant chemotherapy in both the ARH cohort (OR = 0.81, 95% CI = 0.72–0.91) and LRH cohort (OR = 0.69, 95% CI = 0.57–0.82). A similar observation was observed by Matsuo et al. who found that women in the high-volume group were less likely to receive neoadjuvant chemotherapy before RH [10]. Adherence to guidelines by surgeons with different surgical experience merits further exploration.
Numerous factors affect surgical experience. First, surgical experience has been assessed and quantified by different metrics, such as annual surgeon volume (frequency), technique-specific volume, surgeon cumulative volume, and years of experience [14, 38, 39]. Yasunaga et al. [40] defined surgeon volume as the number of radical hysterectomies that each gynaecologist had performed as an operating surgeon over his or her professional career. Their study showed that higher surgeon volume (greater than 200 procedures) was associated with a reduced incidence of postoperative urinary disorders. However, they did not mention the surgical route of RH. Second, surgical educators recognize that skill sets may transfer between operations [41]. Modrall et al. [42] defined the aggregate annual volume per surgeon of upper gastrointestinal operations as the “surrogate volume”, including excision of oesophageal diverticulum, gastrectomy, gastroduodenectomy, and repair of diaphragmatic hernia. Among surgeons with low-volume oesophagectomy experience, increasing the volume of surrogate operations improved the outcomes observed for oesophagectomy. However, there has been little discussion about “surrogate surgery” in gynaecological cancer surgery. It was uncertain whether surrogate operative experiences, such as experiences of extrafascial hysterectomy in benign disease and cytoreductive surgery in ovarian cancer, yield improvements in outcomes for RH. Third, the characteristics of the surgeon, such as age, may have an effect on surgical experience. For example, a surgeon age of ≤ 51 and ≥ 56 years may increase short- and long-term mortality after oesophagectomy for cancer, as the highest surgical competence is achieved between 52 and 56 years of surgeon age [43]. The reason for the decreasing performance among older surgeons might be related to mental fatigue, poorer compliance with evidence-based medicine, and higher administrative positions leading to reduced surgical frequency [38].
Currently, artificial intelligence (AI) can be applied for the prediction, screening, detection of cervical cancer or precancerous lesion and predicting the prognosis of patients [44, 45]. In addition, AI has the potential to distinguish surgeon experience and to provide access to standard surgical solutions that are independent of individuals’ experience and day-to-day performance changes. Chen et al.’s study demonstrated that machine learning can accurately classify surgeon experience based on individual stitches and sub-stitches in the vesico-urethral anastomosis of a robot-assisted radical prostatectomy [46]. Saeidi et al. achieved the enhanced autonomy necessary to perform robotic laparoscopic anastomosis of the small bowel using the Smart Tissue Autonomous Robot (STAR) and they found that autonomous robotic laparoscopic surgery outperforms expert surgeons’ manual technique and robot-assisted surgery technique in terms of consistency and accuracy during laparoscopic small bowel anastomosis experiments [47].
This population-based study is the first to examine changes in the number of surgeons and annual surgeon volume for cervical cancer over time, and to explore the association between surgeon volume and complications after ARH and LRH in China. First, a strength of our study is its large sample size. We reviewed 22,684 cases treated at 42 hospitals over a 13-year period so that data on the rare adverse events could be collected. Second, we also included clinical characteristics, such as FIGO stage, histology, preoperative treatment, hysterectomy type, and lymph node dissection type which may influence the treatment outcome [23].
We also recognize several limitations to our findings. First, this study was a retrospective study in which the data were obtained from inpatient medical records or through readmission. Data on complications that may have occurred after discharge and that would have been treated by other hospitals could not be obtained. Therefore, future well-designed and prospective studies are needed to verify the work with a much larger cohort of patients. Second, we divided the patients into tertiles based on annualized surgeon volumes, but the results of the present study could not translate into clinically meaningful cut-off points. Third, although we considered a wide range of clinical characteristics and tumour characteristics, there might be other unmeasured confounding factors affecting complications, such as assistant surgeons [48], uterine size, downstream care, surgical instruments, management of complications, preoperative frailty scores [49] and subspecialty training background of each surgeon. In addition, skill transference between LRH and ARH remains unclear. Fourth, our study included only patients from 42 hospitals and the findings may not be representative of other areas in China.

Conclusion

In the ARH cohort, the association between surgeon volume and complications for cervical cancer was complex with an increased risk of postoperative complications among intermediate-volume surgeons but the lowest postoperative complication rates for the highest-volume surgeons. In the LRH cohort, surgeon volume appeared to have no significant predictive value for complications.

Acknowledgements

We are grateful to Min Hao (Department of Obstetrics and Gynecology, The Second Hospital of ShanXi Medical University), Wuliang Wang (Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University), Ying Yang (Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University), Shan Kang (Department of Obstetrics and Gynecology, The Fourth Hospital of Hebei Medical University & The Tumor Hospital of Hebei Province), Bin Ling (Department of Obstetrics and Gynecology, China-Japan Friendship Hospital), Xinli Sun and Hongwei Zhao (Department of Gynecology, Shanxi Provincial Cancer Hospital), Yu Guo and Lihong Lin (Department of Gynecology, Anyang Tumor Hospital), Li Wang (Department of Gynecology, The Affiliated Tumor Hospital of Zhengzhou University), Weidong Zhao (Department of Gynecology and Oncology, Anhui Provincial Cancer Hospital), Yan Ni (Department of Obstetrics and Gynecology, The Yuncheng Central Hospital of Shanxi province), Donglin Li and Wentong Liang (Department of Obstetrics and Gynecology, Guizhou Provincial People`s Hospital), Jianxin Guo (Department of Obstetrics and Gynecology, Daping Hospital, The Third Military Medical University), Xuemei Zhan and Mingwei Li (Department of Gynecology, Jiangmen Central Hospital), Weifeng Zhang (Department of Obstetrics and Gynecology, Ningbo Women & Children's Hospital), Peiyan Du (Department of Gynecological Oncology, Cancer Center of Guangzhou Medical University), Ziyu Fang (Department of Obstetrics and Gynecology, Liuzhou Workers' Hospital), Long Chen (Department of Obstetrics and Gynecology, Qingdao Municipal Hospital), Encheng Dai and Ruilei Liu (Department of Obstetrics and Gynecology, Linyi People's Hospital), Mubiao Liu and Yuanli He (Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University), Jilong Yao and Zhihua Liu (Department of Obstetrics and Gynecology, Shenzhen Maternity & Child Healthcare Hospital), Xueqin Wang (Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Southern Medical University), Yan Xu (Department of Obstetrics and Gynecology, Guangzhou Panyu Central Hospital), Ben Ma (Department of Obstetrics and Gynecology, Guangzhou First People's Hospital), Zhonghai Wang (Department of Obstetrics and Gynecology, Shenzhen Nanshan People's Hospital), Lin Zhu (Department of Gynecology, The Second Hospital of Shandong University), Hongxin Pan (Department of Obstetrics and Gynecology, the 3rd Affiliated Hospital of Shenzhen University, Luohu People's Hospital), Qianyong Zhu (Department of Obstetrics and Gynecology, No.153. Centre Hospital of Liberation Army, Hospital No.988 of the Chinese People's Liberation Army Joint Support Force), Xiaohong Wang (Department of Obstetrics and Gynecology, Jinan City People's Hospital, Former Laiwu People's Hospital), Dingyuan Zeng and Zhong Lin (Department of Obstetrics and Gynecology, Maternal and Child Health Care Hospital of Liuzhou), Shaoguang Wang (Department of Obstetrics and Gynecology, Yantai Yuhuangding Hospital), Bin Zhu (Department of Obstetrics and Gynecology, Yiwu Maternal and Child Health Hospital), Anwei Lu (Department of Obstetrics and Gynecology, Maternal and Child Health Care Hospital of Guizhou Province), Mei Ji (Department of Obstetrics and Gynecology, the First Affiliated Hospital of Zhengzhou University), Qianqing Wang (Department of Obstetrics and Gynecology, Central Hospital Affiliated to Xinxiang Medical University), Zhumei Cui (Department of Gynecology, The Affiliated Hospital of Qingdao University Medical College), Biliang Chen (Department of Gynecology, Xijing Hospital of Air Force Medical University), Qinghuang Xie (Department of Gynecology, Foshan Women and Children Hospital), Qiubo Lv (Department of Gynecology, Beijing Hospital), Chang Liu (Department of Gynecology, the First Hospital of Lanzhou University), and Yi Zhang (Department of Gynecology, the First Hospital of China Medical University) for providing medical records.

Declarations

Ethical approval was obtained from Institutional Ethics Committee of Southern Medical University Nanfang Hospital (NFEC-2017-135). The survey protocol was approved by the Institutional Ethics Committee of Southern Medical University Nanfang Hospital (NFEC-2017-135), and we obtained informed consent exemptions approved by Institutional Ethics Committee of Southern Medical University Nanfang Hospital. All methods were performed in accordance with the relevant guidelines and regulations.
Not applicable.

Competing interests

The author(s) declare no potential conflicts of interest for the research, authorship, and/or publication of this article.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
Zurück zum Zitat Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155(S1):28–44.CrossRef Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynecol Obstet. 2021;155(S1):28–44.CrossRef
3.
Zurück zum Zitat Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR. Cervical Cancer, Version 32019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(1):64–84.PubMedCrossRef Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR. Cervical Cancer, Version 32019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(1):64–84.PubMedCrossRef
5.
Zurück zum Zitat Matsuo K, Matsuzaki S, Mandelbaum RS, Chang EJ, Klar M, Matsushima K, et al. Minimally invasive radical hysterectomy for early-stage cervical cancer: volume-outcome relationship in the early experience period. Gynecol Oncol 2020;158(2):390–96.PubMedPubMedCentralCrossRef Matsuo K, Matsuzaki S, Mandelbaum RS, Chang EJ, Klar M, Matsushima K, et al. Minimally invasive radical hysterectomy for early-stage cervical cancer: volume-outcome relationship in the early experience period. Gynecol Oncol 2020;158(2):390–96.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Likic IS, Kadija S, Ladjevic NG, Stefanovic A, Jeremic K, Petkovic S, et al. Analysis of urologic complications after radical hysterectomy. Am J Obstet Gynecol. 2008;199(6):641–4.CrossRef Likic IS, Kadija S, Ladjevic NG, Stefanovic A, Jeremic K, Petkovic S, et al. Analysis of urologic complications after radical hysterectomy. Am J Obstet Gynecol. 2008;199(6):641–4.CrossRef
7.
Zurück zum Zitat Uppal S, Rebecca LJ, Kevin RR, Rice LW, Spencer RJ. Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012–2015). Gynecol Oncol. 2019;152(1):133–8.PubMedCrossRef Uppal S, Rebecca LJ, Kevin RR, Rice LW, Spencer RJ. Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012–2015). Gynecol Oncol. 2019;152(1):133–8.PubMedCrossRef
8.
Zurück zum Zitat Cibula D, Planchamp F, Fischerova D, Fotopoulou C, Kohler C, Landoni F, et al. European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. Int J Gynecol Cancer. 2020;30(1):3–14.PubMedCrossRef Cibula D, Planchamp F, Fischerova D, Fotopoulou C, Kohler C, Landoni F, et al. European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. Int J Gynecol Cancer. 2020;30(1):3–14.PubMedCrossRef
9.
Zurück zum Zitat Matsuo K, Matsuzaki S, Mandelbaum RS, Matsushima K, Klar M, Grubbs BH, et al. Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: a national study in the United States. Gynecol Oncol. 2020;157(1):173–80.PubMedPubMedCentralCrossRef Matsuo K, Matsuzaki S, Mandelbaum RS, Matsushima K, Klar M, Grubbs BH, et al. Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: a national study in the United States. Gynecol Oncol. 2020;157(1):173–80.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Matsuo K, Shimada M, Yamaguchi S, Matoda M, Nakanishi T, Kikkawa F, et al. Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol. 2019;133(6):1086–98.PubMedPubMedCentralCrossRef Matsuo K, Shimada M, Yamaguchi S, Matoda M, Nakanishi T, Kikkawa F, et al. Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol. 2019;133(6):1086–98.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Wright JD, Huang Y, Ananth CV, Tergas AI, Duffy C, Deutsch I, et al. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. Gynecol Oncol. 2015;139(3):506–12.PubMedPubMedCentralCrossRef Wright JD, Huang Y, Ananth CV, Tergas AI, Duffy C, Deutsch I, et al. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. Gynecol Oncol. 2015;139(3):506–12.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–27.PubMedCrossRef Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–27.PubMedCrossRef
13.
Zurück zum Zitat Leow JJ, Reese S, Trinh QD, Bellmunt J, Chung BI, Kibel AS, et al. Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015;115(5):713–21.PubMedCrossRef Leow JJ, Reese S, Trinh QD, Bellmunt J, Chung BI, Kibel AS, et al. Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015;115(5):713–21.PubMedCrossRef
14.
Zurück zum Zitat Yeo HL, Abelson JS, Mao J, O’Mahoney PRA, Milsom JW, Sedrakyan A. Surgeon annual and cumulative volumes predict early postoperative outcomes after rectal cancer resection. Ann Surg. 2017;265(1):151–7.PubMedCrossRef Yeo HL, Abelson JS, Mao J, O’Mahoney PRA, Milsom JW, Sedrakyan A. Surgeon annual and cumulative volumes predict early postoperative outcomes after rectal cancer resection. Ann Surg. 2017;265(1):151–7.PubMedCrossRef
15.
Zurück zum Zitat Ramakrishna R, Hsu WC, Mao J, Sedrakyan S. Surgeon annual and cumulative volumes predict early postoperative outcomes after brain tumor resection. World Neurosurg. 2018;114:e254–66.PubMedCrossRef Ramakrishna R, Hsu WC, Mao J, Sedrakyan S. Surgeon annual and cumulative volumes predict early postoperative outcomes after brain tumor resection. World Neurosurg. 2018;114:e254–66.PubMedCrossRef
16.
Zurück zum Zitat Pointer DJ, Al-Qurayshi Z, Hamner JB, Slakey DP, Kandil E. Factors leading to pancreatic resection in patients with pancreatic cancer: a national perspective. Gland Surg. 2018;7(2):207–15.PubMedPubMedCentralCrossRef Pointer DJ, Al-Qurayshi Z, Hamner JB, Slakey DP, Kandil E. Factors leading to pancreatic resection in patients with pancreatic cancer: a national perspective. Gland Surg. 2018;7(2):207–15.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Wright JD, Ruiz MP, Chen L, Gabor LR, Tergas AI, Clairet CMS, et al. Changes in surgical volume and outcomes over time for women undergoing hysterectomy for endometrial cancer. Obstet Gynecol. 2018;132(1):59–69.PubMedPubMedCentralCrossRef Wright JD, Ruiz MP, Chen L, Gabor LR, Tergas AI, Clairet CMS, et al. Changes in surgical volume and outcomes over time for women undergoing hysterectomy for endometrial cancer. Obstet Gynecol. 2018;132(1):59–69.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Clark JM, Cooke DT, Chin DL, Utter GH, Brown LM, Nuño M. Does one size fit all? An evaluation of the 2018 Leapfrog Group minimal hospital and surgeon volume thresholds for lung surgery. J Thorac Cardiovasc Surg. 2020;159(5):2071–9.PubMedCrossRef Clark JM, Cooke DT, Chin DL, Utter GH, Brown LM, Nuño M. Does one size fit all? An evaluation of the 2018 Leapfrog Group minimal hospital and surgeon volume thresholds for lung surgery. J Thorac Cardiovasc Surg. 2020;159(5):2071–9.PubMedCrossRef
19.
Zurück zum Zitat Clark JM, Cooke DT, Hashimi H, Chin D, Utter GH, Brown LM, et al. Do the 2018 Leapfrog group minimal hospital and surgeon volume thresholds for esophagectomy favor specific patient demographics? Ann surg. 2021;274(3):e220–9.PubMedCrossRef Clark JM, Cooke DT, Hashimi H, Chin D, Utter GH, Brown LM, et al. Do the 2018 Leapfrog group minimal hospital and surgeon volume thresholds for esophagectomy favor specific patient demographics? Ann surg. 2021;274(3):e220–9.PubMedCrossRef
20.
Zurück zum Zitat Aning JJ, Reilly GS, Fowler S, Challacombe B, McGrath JS, Sooriakumaran P. Perioperative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon-reported data. BJU Int. 2019;124(3):441–8.PubMedCrossRef Aning JJ, Reilly GS, Fowler S, Challacombe B, McGrath JS, Sooriakumaran P. Perioperative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon-reported data. BJU Int. 2019;124(3):441–8.PubMedCrossRef
21.
Zurück zum Zitat Rutegård M, Lagergren J, Rouvelas I, Lagergren P. Surgeon volume is a poor proxy for skill in esophageal cancer surgery. Ann Surg. 2009;249(2):256–61.PubMedCrossRef Rutegård M, Lagergren J, Rouvelas I, Lagergren P. Surgeon volume is a poor proxy for skill in esophageal cancer surgery. Ann Surg. 2009;249(2):256–61.PubMedCrossRef
22.
Zurück zum Zitat Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2011;205(3):221–5.CrossRef Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2011;205(3):221–5.CrossRef
23.
Zurück zum Zitat Liang C, Liu P, Cui Z, Liang Z, Bin X, Lang J, et al. Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIB cervical cancer in China, 2004–2015. Gynecol Oncol. 2020;156(1):115–23.PubMedCrossRef Liang C, Liu P, Cui Z, Liang Z, Bin X, Lang J, et al. Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIB cervical cancer in China, 2004–2015. Gynecol Oncol. 2020;156(1):115–23.PubMedCrossRef
24.
Zurück zum Zitat Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9(3):297–303.PubMedCrossRef Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008;9(3):297–303.PubMedCrossRef
25.
Zurück zum Zitat Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M, Tashiro H, et al. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2019;24(1):1–19.PubMedCrossRef Ebina Y, Mikami M, Nagase S, Tabata T, Kaneuchi M, Tashiro H, et al. Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2019;24(1):1–19.PubMedCrossRef
26.
Zurück zum Zitat Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:V72–83.CrossRef Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:V72–83.CrossRef
27.
Zurück zum Zitat Wright JD, Hershman DL, Burke WM, Lu YS, Neugut AI, Lewin SN, et al. Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol. 2012;19(3):948–58.PubMedCrossRef Wright JD, Hershman DL, Burke WM, Lu YS, Neugut AI, Lewin SN, et al. Influence of surgical volume on outcome for laparoscopic hysterectomy for endometrial cancer. Ann Surg Oncol. 2012;19(3):948–58.PubMedCrossRef
28.
Zurück zum Zitat Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, et al. Effect of minimum-volume standards on patient outcomes and surgical practice patterns for hysterectomy. Obstet Gynecol. 2018;132(5):1229–37.PubMedPubMedCentralCrossRef Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, et al. Effect of minimum-volume standards on patient outcomes and surgical practice patterns for hysterectomy. Obstet Gynecol. 2018;132(5):1229–37.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379(20):1895–904.PubMedCrossRef Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379(20):1895–904.PubMedCrossRef
30.
Zurück zum Zitat Bogani G, Di Donato V, Scambia G, Raspagliesi F, Chiantera V, Sozzi G, et al. Radical hysterectomy for early stage cervical cancer. Int J Enviorn Res Public Health. 2022;19(18):11641.CrossRef Bogani G, Di Donato V, Scambia G, Raspagliesi F, Chiantera V, Sozzi G, et al. Radical hysterectomy for early stage cervical cancer. Int J Enviorn Res Public Health. 2022;19(18):11641.CrossRef
31.
Zurück zum Zitat Bogani G, Donato VD, Scambia G, Landoni F, Ghezzi F, Muzii L, et al. Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer. Gynecol Oncol. 2022;166(3):561–6.PubMedCrossRef Bogani G, Donato VD, Scambia G, Landoni F, Ghezzi F, Muzii L, et al. Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer. Gynecol Oncol. 2022;166(3):561–6.PubMedCrossRef
32.
Zurück zum Zitat D’Oria O, Corrado G, Laganà AS, Chiantera V, Vizza E, Giannini A. New advances in cervical cancer: from bench to bedside. Int J Env Res Pub Health. 2022;19(12):7094.CrossRef D’Oria O, Corrado G, Laganà AS, Chiantera V, Vizza E, Giannini A. New advances in cervical cancer: from bench to bedside. Int J Env Res Pub Health. 2022;19(12):7094.CrossRef
33.
Zurück zum Zitat Pecorino B. D’Agate MG, Scibilia G, Scollo P, Giannini A, Di Donna MC, et al. Evaluation of surgical outcomes of abdominal radical hysterectomy and total laparoscopic radical hysterectomy for cervical cancer: a retrospective analysis of data collected before the LACC Trial. Int J Env Res Pub He. 2022;19(20):13176.CrossRef Pecorino B. D’Agate MG, Scibilia G, Scollo P, Giannini A, Di Donna MC, et al. Evaluation of surgical outcomes of abdominal radical hysterectomy and total laparoscopic radical hysterectomy for cervical cancer: a retrospective analysis of data collected before the LACC Trial. Int J Env Res Pub He. 2022;19(20):13176.CrossRef
34.
Zurück zum Zitat Giannini A, D’Oria O, Chiantera V, Margioula-Siarkou C, Di Donna MC, Terzic S, et al. Minimally invasive surgery for cervical cancer: should we look beyond squamous cell carcinoma? J Invest Surg. 2022;35(7):1602–3.PubMedCrossRef Giannini A, D’Oria O, Chiantera V, Margioula-Siarkou C, Di Donna MC, Terzic S, et al. Minimally invasive surgery for cervical cancer: should we look beyond squamous cell carcinoma? J Invest Surg. 2022;35(7):1602–3.PubMedCrossRef
35.
Zurück zum Zitat Kim SI, Lee J, Hong J, Lee SJ, Park DC, Yoon JH. Comparison of abdominal and minimally invasive radical hysterectomy in patients with early stage cervical cancer. Int J Med Sci. 2021;18(5):1312–7.PubMedPubMedCentralCrossRef Kim SI, Lee J, Hong J, Lee SJ, Park DC, Yoon JH. Comparison of abdominal and minimally invasive radical hysterectomy in patients with early stage cervical cancer. Int J Med Sci. 2021;18(5):1312–7.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol. 2011;117(5):1051–9.PubMedCrossRef Wright JD, Lewin SN, Deutsch I, Burke WM, Sun X, Herzog TJ. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol. 2011;117(5):1051–9.PubMedCrossRef
37.
Zurück zum Zitat Tunitsky E, Citil A, Ayaz R, Esin S, Knee A, Harmanli O. Does surgical volume influence short-term outcomes of laparoscopic hysterectomy? Am J Obstet Gynecol. 2010;203(1):21–4.CrossRef Tunitsky E, Citil A, Ayaz R, Esin S, Knee A, Harmanli O. Does surgical volume influence short-term outcomes of laparoscopic hysterectomy? Am J Obstet Gynecol. 2010;203(1):21–4.CrossRef
38.
Zurück zum Zitat Maruthappu M, Gilbert BJ, El-Harasis MA, Nagendran M, McCulloch P, Duclos A, et al. The influence of volume and experience on individual surgical performance. Ann Surg. 2015;261(4):642–7.PubMedCrossRef Maruthappu M, Gilbert BJ, El-Harasis MA, Nagendran M, McCulloch P, Duclos A, et al. The influence of volume and experience on individual surgical performance. Ann Surg. 2015;261(4):642–7.PubMedCrossRef
39.
Zurück zum Zitat Cusimano MC, Baxter NN, Gien LT, Moineddin R, Liu N, Dossa F, et al. Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer. AM J Obstet Gynecol. 2019;221(6):611–9.CrossRef Cusimano MC, Baxter NN, Gien LT, Moineddin R, Liu N, Dossa F, et al. Impact of surgical approach on oncologic outcomes in women undergoing radical hysterectomy for cervical cancer. AM J Obstet Gynecol. 2019;221(6):611–9.CrossRef
40.
Zurück zum Zitat Yasunaga H, Nishii O, Hirai Y, Ochiai K, Matsuyama Y, Ohe K. Impact of surgeon and hospital volumes on short-term postoperative complications after radical hysterectomy for cervical cancer. J Obstet Gynaecol Res. 2009;35(4):699–705.PubMedCrossRef Yasunaga H, Nishii O, Hirai Y, Ochiai K, Matsuyama Y, Ohe K. Impact of surgeon and hospital volumes on short-term postoperative complications after radical hysterectomy for cervical cancer. J Obstet Gynaecol Res. 2009;35(4):699–705.PubMedCrossRef
41.
Zurück zum Zitat Modrall JG, Chung J, Kirkwood ML, Baig MS, TsaiTimaran SXCH, et al. Low rates of complications for carotid artery stenting are associated with a high clinician volume of carotid artery stenting and aortic endografting but not with a high volume of percutaneous coronary interventions. J Vasc Surg. 2014;60(1):70–6.PubMedCrossRef Modrall JG, Chung J, Kirkwood ML, Baig MS, TsaiTimaran SXCH, et al. Low rates of complications for carotid artery stenting are associated with a high clinician volume of carotid artery stenting and aortic endografting but not with a high volume of percutaneous coronary interventions. J Vasc Surg. 2014;60(1):70–6.PubMedCrossRef
42.
Zurück zum Zitat Modrall JG, Minter RM, Minhajuddin A, Eslava-Schmalbach J, Joshi GP, Patel S, et al. The surgeon volume-outcome relationship: not yet ready for policy. Ann Surg. 2018;267(5):863–7.PubMedCrossRef Modrall JG, Minter RM, Minhajuddin A, Eslava-Schmalbach J, Joshi GP, Patel S, et al. The surgeon volume-outcome relationship: not yet ready for policy. Ann Surg. 2018;267(5):863–7.PubMedCrossRef
43.
Zurück zum Zitat Markar SR, Mackenzie H, Lagergren P, Lagergren J. Surgeon age in relation to prognosis after esophageal cancer resection. Ann Surg. 2018;268(1):100–5.PubMedCrossRef Markar SR, Mackenzie H, Lagergren P, Lagergren J. Surgeon age in relation to prognosis after esophageal cancer resection. Ann Surg. 2018;268(1):100–5.PubMedCrossRef
44.
Zurück zum Zitat Allahqoli L, Laganà AS, Mazidimoradi A, Salehiniya H, Günther V, Chiantera V, et al. Diagnosis of cervical cancer and pre-cancerous lesions by artificial intelligence: a systematic review. Diagnostics. 2022;12(11):2771.PubMedPubMedCentralCrossRef Allahqoli L, Laganà AS, Mazidimoradi A, Salehiniya H, Günther V, Chiantera V, et al. Diagnosis of cervical cancer and pre-cancerous lesions by artificial intelligence: a systematic review. Diagnostics. 2022;12(11):2771.PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Obrzut B, Kusy M, Semczuk A, Obrzut M, Kluska J. Prediction of 5–year overall survival in cervical cancer patients treated with radical hysterectomy using computational intelligence methods. BMC Cancer. 2017;17(1):840.CrossRef Obrzut B, Kusy M, Semczuk A, Obrzut M, Kluska J. Prediction of 5–year overall survival in cervical cancer patients treated with radical hysterectomy using computational intelligence methods. BMC Cancer. 2017;17(1):840.CrossRef
46.
Zurück zum Zitat Chen AB, Liang S, Nguyen JH, Liu Y, Hung AJ. Machine learning analyses of automated performance metrics during granular sub-stitch phases predict surgeon experience. Surgery. 2021;169(5):1245–9.PubMedCrossRef Chen AB, Liang S, Nguyen JH, Liu Y, Hung AJ. Machine learning analyses of automated performance metrics during granular sub-stitch phases predict surgeon experience. Surgery. 2021;169(5):1245–9.PubMedCrossRef
47.
Zurück zum Zitat Saeidi H, Opfermann JD, Kam M, Wei S, Leonard S, Hsieh MH, et al. Autonomous robotic laparoscopic surgery for intestinal anastomosis. Sci Robotics. 2022;7(62):eabj2908.CrossRef Saeidi H, Opfermann JD, Kam M, Wei S, Leonard S, Hsieh MH, et al. Autonomous robotic laparoscopic surgery for intestinal anastomosis. Sci Robotics. 2022;7(62):eabj2908.CrossRef
48.
Zurück zum Zitat Deery SE, O’Donnell TFX, Zettervall SL, Darling JD, Shean KE, O’Malley AJ, et al. Use of an assistant surgeon does not mitigate the effect of lead surgeon volume on outcomes following open repair of intact abdominal aortic aneurysms. Eur J Vasc Endovasc. 2018;55(5):714–9.CrossRef Deery SE, O’Donnell TFX, Zettervall SL, Darling JD, Shean KE, O’Malley AJ, et al. Use of an assistant surgeon does not mitigate the effect of lead surgeon volume on outcomes following open repair of intact abdominal aortic aneurysms. Eur J Vasc Endovasc. 2018;55(5):714–9.CrossRef
49.
Zurück zum Zitat D’Oria O, Golia D’Augè T, Baiocco E, Vincenzoni C, Mancini A, Bruno V, et al. The role of preoperative frailty assessment in patients affected by gynecological cancer: a narrative review. Italian J Gynaecol Obstet. 2022;34(2):76–83.CrossRef D’Oria O, Golia D’Augè T, Baiocco E, Vincenzoni C, Mancini A, Bruno V, et al. The role of preoperative frailty assessment in patients affected by gynecological cancer: a narrative review. Italian J Gynaecol Obstet. 2022;34(2):76–83.CrossRef
Metadaten
Titel
Effect of annualized surgeon volume on major surgical complications for abdominal and laparoscopic radical hysterectomy for cervical cancer in China, 2004–2016: a retrospective cohort study
verfasst von
Cong Liang
Weili Li
Xiaoyun Liu
Hongwei Zhao
Lu Yin
Mingwei Li
Yu Guo
Jinghe Lang
Xiaonong Bin
Ping Liu
Chunlin Chen
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
BMC Women's Health / Ausgabe 1/2023
Elektronische ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-023-02213-6

Weitere Artikel der Ausgabe 1/2023

BMC Women's Health 1/2023 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.